Salix Pharmaceuticals Presents Xifaxan Analysis at ACG 2024

Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced significant presentations at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting in Philadelphia. These presentations focus on Xifaxan (rifaximin) and its efficacy in reducing overt hepatic encephalopathy (OHE) recurrence and rehospitalizations.

Key findings include a post hoc analysis indicating that Xifaxan monotherapy is more effective than lactulose in reducing OHE recurrence and all-cause mortality. Additional data highlights the impact of Xifaxan on OHE rehospitalizations in commercially and Medicare insured populations.

Salix will also present findings on Plenvu, a bowel preparation solution. These include results from colonoscopy patients with comorbid conditions or concomitant medication use.